ARCHIVES

FDA Describes Meeting With NCI In “Limited” Memo

This article is from The Cancer Letter archive.

Vol. 02 No. 19 | May 7, 1976

Download PDF Visit The Full Archive

Related Articles

Two Second-Line CML Drugs Work Front-Line, Studies Find

January 29, 2010

In Brief: ESMO Names Annual Award Winners

October 10, 2014

AZURE Trial: Zoledronic Acid Didn’t Improve DFS In Stage II/III

December 31, 2010

Niccotine Reports As Aiding Metastasis

August 22, 1986

“The One Thing You Want From AN NCI Director: He Will Be Bound By The Facts”

October 28, 1994

DOD To Reimburse Care On Clinical Trials In Three-Year Deal

February 9, 1996